Announced Thu, 21 May · 13:16 IST

Newspaper advertisement of Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and year ended March 31, 2026, approved at the meeting of Board of Directors ....

HCG · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.8%1-day move
₹650.00
prior close
₹631.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.1+0.2-1.1-0.3+0.8+1.2+0.9+1.5-2.3-2.8-3.1-5.5+2.0
Up moveDown movePending
AI summary

Healthcare Global Enterprises (HCG) published its audited financial results for Q4 and full year FY26 (ending March 31, 2026), approved by the Board on May 19, 2026. Consolidated total income for FY26 was Rs 2,803.89 Lakhs vs Rs 3,074.78 Lakhs in FY25, showing a decline. However, the company returned to profitability with consolidated net profit of Rs 68.65 Lakhs in FY26 compared to a net loss of Rs 216.21 Lakhs in FY25. The standalone figures show similar trends with income declining year-on-year but profitability improving. EPS for FY26 (consolidated) stood at Rs 0.34 versus a loss per share of Rs 1.05 in the prior year. The results were reviewed by the Audit Committee and audited by the Statutory Auditors under SEBI LODR regulations.

Likely market impact

HCG swung from a loss to profitability in FY26, a positive signal, though revenue declined year-on-year, indicating possible cost optimization or volume challenges. Shareholders should focus on Q4 performance and revenue trajectory for further insights.